STR V003
Alternative Names: STR-V003Latest Information Update: 23 Apr 2024
At a glance
- Originator Starna Therapeutics
- Class RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Respiratory syncytial virus infections
Most Recent Events
- 10 Apr 2024 Preclinical trials in Respiratory syncytial virus infections in China (IM) before April 2024
- 10 Apr 2024 Starna Therapeutics plans a phase I/II trial for Respiratory syncytial virus infections (Prevention) in China (IM, Injection) in May 2024(NCT06344975)